Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tiotropium bromide.

Nicholas J Gross1

  • 1Hines VA Hospital, PO Box 1485, Hines, IL 60141, USA. Nicholas.gross@med.va.gov

Chest
|December 15, 2004
PubMed
Summary
This summary is machine-generated.

Tiotropium bromide, a once-daily inhaled anticholinergic, offers prolonged bronchodilation for COPD patients. It improves lung function, quality of life, and reduces exacerbations, demonstrating superior efficacy over other treatments with minimal side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease.

International journal of chronic obstructive pulmonary disease·2018
Same author

Nebulized Long-Acting Beta2-Agonists: More Than Just Bridging Gaps in the Management of Symptomatic COPD.

Chronic obstructive pulmonary diseases (Miami, Fla.)·2017
Same author

New Therapies for Asthma and Chronic Obstructive Pulmonary Disease.

American journal of respiratory and critical care medicine·2016
Same author

Rising Costs of COPD and the Potential for Maintenance Therapy to Slow the Trend.

American health & drug benefits·2014
Same author

The COPD pipeline XXIV.

COPD·2013
Same author

The COPD pipeline XXII.

COPD·2013
Same journal

Wearable-derived activity and physiological changes following pleural intervention in malignant pleural effusion.

Chest·2026
Same journal

The effect of a two-day stay at high altitude (2500 m) on right ventricular afterload and oxygen delivery in patients with pulmonary vascular disease A randomized controlled crossover trial.

Chest·2026
Same journal

A Comparative Study of Radiation Exposure in Conventional and Robotic Bronchoscopy.

Chest·2026
Same journal

Independent Prognostic Contributions of Anti-Ro52 and Anti-MDA5 in Autoimmune-Associated Interstitial Lung Disease.

Chest·2026
Same journal

Lung aeration and gas exchange in SGA or AGA infants with moderate-severe BPD: secondary analysis of the PATH-BPD study.

Chest·2026
Same journal

Lung Cancer Incidence and Mortality after Negative Low-Dose CT Screening Results.

Chest·2026
See all related articles

Area of Science:

  • Pharmacology
  • Respiratory Medicine
  • Clinical Trials

Background:

  • Chronic Obstructive Pulmonary Disease (COPD) management requires effective bronchodilators.
  • Existing treatments often necessitate frequent administration.
  • Novel long-acting agents are needed to improve patient adherence and outcomes.

Purpose of the Study:

  • To evaluate the efficacy and safety of tiotropium bromide in COPD patients.
  • To compare tiotropium's bronchodilatory effects and clinical outcomes against ipratropium and salmeterol.
  • To assess the duration of action and side effect profile of tiotropium.

Main Methods:

  • Clinical trials involving COPD patients treated with inhaled tiotropium bromide.
  • Spirometry and lung volume measurements to assess bronchodilation.

Related Experiment Videos

  • Evaluation of patient-reported outcomes including dyspnea, quality of life, and exacerbation rates.
  • Head-to-head comparisons with ipratropium and salmeterol.

    • Main Results:

    • Tiotropium bromide provides bronchodilation lasting over 24 hours due to M3 muscarinic receptor blockade.
    • Significant improvements in spirometry and lung volumes were observed.
    • Clinically relevant benefits include relief of dyspnea, improved quality of life, and reduced exacerbation frequency and severity.
    • Once-daily tiotropium demonstrated statistically superior bronchodilation compared to four-times-daily ipratropium and twice-daily salmeterol.
    • Clinical outcomes were numerically better with tiotropium than salmeterol, though not always statistically significant.

    Conclusions:

    • Tiotropium bromide is an effective and safe once-daily inhaled anticholinergic for COPD.
    • Its prolonged action and significant clinical benefits offer an advantage over existing therapies.
    • Dry mouth is the primary side effect, occurring in 10-16% of patients, with overall good tolerability.